These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8911272)

  • 1. Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy.
    McPherson R; Agnani G; Lau P; Fruchart JC; Edgar AD; Marcel YL
    Arterioscler Thromb Vasc Biol; 1996 Nov; 16(11):1340-6. PubMed ID: 8911272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
    Guérin M; Bruckert E; Dolphin PJ; Turpin G; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):763-72. PubMed ID: 8640404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesteryl ester transfer activity in lipoprotein lipase deficiency and other primary hypertriglyceridemias.
    Iglesias A; Contreras JA; Martínez-Pardo M; Entrala A; Herrera E; Lasunción MA
    Clin Chim Acta; 1993 Nov; 221(1-2):73-89. PubMed ID: 8149644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
    Tilly-Kiesi M; Kahri J; Pyörälä T; Puolakka J; Luotola H; Lappi M; Lahdenperä S; Taskinen MR
    Atherosclerosis; 1997 Mar; 129(2):249-59. PubMed ID: 9105568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia.
    Moulin P; Appel GB; Ginsberg HN; Tall AR
    J Lipid Res; 1992 Dec; 33(12):1817-22. PubMed ID: 1479291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased esterification of cholesterol and transfer of cholesteryl ester to apo B-containing lipoproteins in Type 2 diabetes: relationship to serum lipoproteins A-I and A-II.
    Jones RJ; Owens D; Brennan C; Collins PB; Johnson AH; Tomkin GH
    Atherosclerosis; 1996 Jan; 119(2):151-7. PubMed ID: 8808492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids.
    Iglesias A; Arranz M; Alvarez JJ; Perales J; Villar J; Herrera E; Lasunción MA
    Clin Chim Acta; 1996 Apr; 248(2):157-74. PubMed ID: 8740580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment.
    Korhonen T; Hannuksela ML; Seppänen S; Kervinen K; Kesäniemi YA; Savolainen MJ
    Eur J Clin Pharmacol; 1999 Feb; 54(12):903-10. PubMed ID: 10192749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
    Berti JA; Amaral ME; Boschero AC; Nunes VS; Harada LM; Castilho LN; Oliveira HC
    Metabolism; 2001 May; 50(5):530-6. PubMed ID: 11319713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.
    de Grooth GJ; Kuivenhoven JA; Stalenhoef AF; de Graaf J; Zwinderman AH; Posma JL; van Tol A; Kastelein JJ
    Circulation; 2002 May; 105(18):2159-65. PubMed ID: 11994249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene.
    Raposo HF; Patrício PR; Simões MC; Oliveira HC
    J Nutr Biochem; 2014 Jun; 25(6):669-74. PubMed ID: 24746832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression.
    van der Hoogt CC; de Haan W; Westerterp M; Hoekstra M; Dallinga-Thie GM; Romijn JA; Princen HM; Jukema JW; Havekes LM; Rensen PC
    J Lipid Res; 2007 Aug; 48(8):1763-71. PubMed ID: 17525476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy.
    Bellanger N; Julia Z; Villard EF; El Khoury P; Duchene E; Chapman MJ; Fournier N; Le Goff W; Guerin M
    Atherosclerosis; 2012 Mar; 221(1):160-8. PubMed ID: 22265126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma.
    Murakami T; Michelagnoli S; Longhi R; Gianfranceschi G; Pazzucconi F; Calabresi L; Sirtori CR; Franceschini G
    Arterioscler Thromb Vasc Biol; 1995 Nov; 15(11):1819-28. PubMed ID: 7583561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro production of beta-very low density lipoproteins and small, dense low density lipoproteins in mildly hypertriglyceridemic plasma: role of activities of lecithin:cholester acyltransferase, cholesterylester transfer proteins and lipoprotein lipase.
    Chung BH; Segrest JP; Franklin F
    Atherosclerosis; 1998 Dec; 141(2):209-25. PubMed ID: 9862170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of cholesteryl ester transfer protein-mediated cholesteryl ester mass transfer from high-density lipoprotein to low-density lipoprotein particles is a major feature of combined hyperlipidaemia.
    Guérin M; Bruckert E; Dolphin PJ; Chapman MJ
    Eur J Clin Invest; 1996 Jun; 26(6):485-94. PubMed ID: 8817163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia.
    Guérin M; Dolphin PJ; Talussot C; Gardette J; Berthézène F; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1995 Sep; 15(9):1359-68. PubMed ID: 7670950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.